| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell, Tumor, and Stem Cell Biology |
in Epidermis Reveals Its Role in Suppression of Epithelial Tumorigenesis1 Cell Signaling and Cancer Group, Department of Environmental and Molecular Toxicology and 2 Functional Genomics Program, North Carolina State University, Raleigh, North Carolina and 3 Laboratory of Protein Dynamics and Signaling, National Cancer Institute, Frederick, Maryland
Requests for reprints: Robert C. Smart, Cell Signaling and Cancer Group, Department of Environmental and Molecular Toxicology, North Carolina State University, Campus Box 7633, Raleigh, NC 27695. Phone: 919-515-7245; Fax: 919-515-7169; E-mail: rcsmart{at}ncsu.edu.
CCAAT/enhancer binding protein
(C/EBP
) is a basic leucine zipper transcription factor that inhibits cell cycle progression and regulates differentiation in various cell types. C/EBP
is inactivated by mutation in acute myeloid leukemia (AML) and is considered a human tumor suppressor in AML. Although C/EBP
mutations have not been observed in malignancies other than AML, greatly diminished expression of C/EBP
occurs in numerous human epithelial cancers including lung, liver, endometrial, skin, and breast, suggesting a possible tumor suppressor function. However, direct evidence for C/EBP
as an epithelial tumor suppressor is lacking due to the absence of C/EBP
mutations in epithelial tumors and the lethal effect of C/EBP
deletion in mouse model systems. To examine the function of C/EBP
in epithelial tumor development, an epidermal-specific C/EBP
knockout mouse was generated. The epidermal-specific C/EBP
knockout mice survived and displayed no detectable abnormalities in epidermal keratinocyte proliferation, differentiation, or apoptosis, showing that C/EBP
is dispensable for normal epidermal homeostasis. In spite of this, the epidermal-specific C/EBP
knockout mice were highly susceptible to skin tumor development involving oncogenic Ras. These mice displayed decreased tumor latency and striking increases in tumor incidence, multiplicity, growth rate, and the rate of malignant progression. Mice hemizygous for C/EBP
displayed an intermediate-enhanced tumor phenotype. Our results suggest that decreased expression of C/EBP
contributes to deregulation of tumor cell proliferation. C/EBP
had been proposed to block cell cycle progression through inhibition of E2F activity. We observed that C/EBP
blocked Ras-induced and epidermal growth factor–induced E2F activity in keratinocytes and also blocked Ras-induced cell transformation and cell cycle progression. Our study shows that C/EBP
is dispensable for epidermal homeostasis and provides genetic evidence that C/EBP
is a suppressor of epithelial tumorigenesis. [Cancer Res 2007;67(14):6768–76]
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |